- Home
- JFU vs PULM Comparison
JFU vs PULM Comparison
Compare JFU & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- PULM
- Stock Information
- Founded
- JFU 2006
- PULM 2003
- Country
- JFU China
- PULM United States
- Employees
- JFU N/A
- PULM N/A
- Industry
- JFU Finance: Consumer Services
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- JFU Finance
- PULM Health Care
- Exchange
- JFU Nasdaq
- PULM Nasdaq
- Market Cap
- JFU 17.8M
- PULM 21.0M
- IPO Year
- JFU 2019
- PULM N/A
- Fundamental
- Price
- JFU $1.45
- PULM $8.57
- Analyst Decision
- JFU
- PULM
- Analyst Count
- JFU 0
- PULM 0
- Target Price
- JFU N/A
- PULM N/A
- AVG Volume (30 Days)
- JFU 6.6K
- PULM 42.9K
- Earning Date
- JFU 12-09-2022
- PULM 03-27-2025
- Dividend Yield
- JFU N/A
- PULM N/A
- EPS Growth
- JFU N/A
- PULM N/A
- EPS
- JFU 0.09
- PULM N/A
- Revenue
- JFU $40,614,155.00
- PULM $10,005,000.00
- Revenue This Year
- JFU N/A
- PULM N/A
- Revenue Next Year
- JFU N/A
- PULM $1.00
- P/E Ratio
- JFU $14.70
- PULM N/A
- Revenue Growth
- JFU N/A
- PULM 47.05
- 52 Week Low
- JFU $1.13
- PULM $1.55
- 52 Week High
- JFU $3.75
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- JFU 46.78
- PULM 55.25
- Support Level
- JFU $1.37
- PULM $6.43
- Resistance Level
- JFU $1.56
- PULM $7.68
- Average True Range (ATR)
- JFU 0.09
- PULM 0.57
- MACD
- JFU -0.01
- PULM -0.01
- Stochastic Oscillator
- JFU 30.77
- PULM 76.29
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.